Targeting neutrophils in asthma: A therapeutic opportunity?
Targeting neutrophils in asthma: A therapeutic opportunity?
复制标题
DOI：
10.1016/j.bcp.2020.114292
复制
发表时间：
2020-12-01
影响因子：
5.8
通讯作者：
Maes, Tania
中科院分区：
文献类型：
--
作者：
De Volder, Joyceline;Vereecke, Lars;Maes, Tania
吸入糖皮质激素抑制气道炎症一直是治疗哮喘的主要方法。此外，哮喘中炎性表型的鉴定导致了重要的突破，例如特异性靶向IL-5途径作为难治性嗜酸性粒细胞性哮喘的附加治疗。然而，与哮喘的嗜中性粒细胞成分的干扰的影响是较少的文件和understanding.This审查提供了一个概述，建立和最近的见解，在哮喘中的作用，中性粒细胞，重点在人类的研究。我们将描述哮喘中嗜中性粒细胞反应的主要驱动因素，中性粒细胞的异质性以及它们如何有助于哮喘发病机制。此外，我们将描述临床试验的结果，其中嗜酸性炎症是目标。很明显，中性粒细胞是哮喘发展的重要因素，并在哮喘加重中发挥作用。然而，还需要更多的研究来充分了解调节中性粒细胞活性如何使伴有气道嗜中性粒细胞的哮喘患者获得显著的益处。
Suppression of airway inflammation with inhaled corticosteroids has been the key therapeutic approach for asthma for many years. Identification of inflammatory phenotypes in asthma has moreover led to important breakthroughs, e.g. with specific targeting of the IL-5 pathway as add-on treatment in difficult-to-treat eosinophilic asthma. However, the impact of interfering with the neutrophilic component in asthma is less documented and understood.This review provides an overview of established and recent insights with regard to the role of neutrophils in asthma, focusing on research in humans. We will describe the main drivers of neutrophilic responses in asthma, the heterogeneity in neutrophils and how they could contribute to asthma pathogenesis. Moreover we will describe findings from clinical trials, in which neutrophilic inflammation was targeted. It is clear that neutrophils are important actors in asthma development and play a role in exacerbations. However, more research is required to fully understand how modulation of neutrophil activity could lead to a significant benefit in asthma patients with airway neutrophilia.